NasdaqGS - Delayed Quote • USD
Galapagos NV (GLPG)
At close: April 18 at 4:00 PM EDT
Pre-Market: 4:55 AM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 6 | 5 |
| Avg. Estimate | -0.14 | -0.08 | -1.04 | -1.27 |
| Low Estimate | -0.32 | -0.33 | -2.79 | -2.93 |
| High Estimate | 0.02 | 0.15 | 0.37 | 0.27 |
| Year Ago EPS | 0.37 | 0.08 | 3.41 | -1.04 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 7 | 7 |
| Avg. Estimate | 69.97M | 69.32M | 305.02M | 299.12M |
| Low Estimate | 63.19M | 61.12M | 245.5M | 249.61M |
| High Estimate | 78.98M | 79.1M | 437.23M | 386.92M |
| Year Ago Sales | 188.94M | 158.4M | 832.13M | 305.02M |
| Sales Growth (year/est) | -63.00% | -56.20% | -63.30% | -1.90% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.92 | -0.74 | -0.67 | -1.25 |
| EPS Actual | 0.37 | 0.08 | 0.43 | 2.54 |
| Difference | 1.29 | 0.82 | 1.1 | 3.79 |
| Surprise % | 140.20% | 110.80% | 164.20% | 303.20% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.14 | -0.08 | -1.04 | -1.27 |
| 7 Days Ago | -0.25 | -0.19 | -1.27 | -1.53 |
| 30 Days Ago | -0.25 | -0.19 | -1.75 | -2.06 |
| 60 Days Ago | -1 | -0.94 | -2.61 | -2.93 |
| 90 Days Ago | -1.01 | -0.95 | -2.76 | -2.73 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 1 | 1 | 1 |
| Up Last 30 Days | 1 | 1 | 2 | 2 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | GLPG | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -137.80% | -- | -- | 0.80% |
| Next Qtr. | -200.00% | -- | -- | 9.60% |
| Current Year | -130.50% | -- | -- | 4.50% |
| Next Year | -22.10% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 47.44% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Downgrade | B of A Securities: Neutral to Underperform | 4/1/2024 |
| Downgrade | B of A Securities: Neutral to Underperform | 3/28/2024 |
| Maintains | B of A Securities: Neutral to Neutral | 1/2/2024 |
| Maintains | Morgan Stanley: Equal-Weight to Equal-Weight | 8/7/2023 |
| Reiterates | Morgan Stanley: Equal-Weight to Equal-Weight | 8/1/2023 |
| Reiterates | Morgan Stanley: Equal-Weight to Equal-Weight | 7/31/2023 |
Related Tickers
ASMB Assembly Biosciences, Inc.
13.33
+2.85%
NXTC NextCure, Inc.
1.5700
+3.97%
CTMX CytomX Therapeutics, Inc.
1.7300
-1.70%
SPRO Spero Therapeutics, Inc.
1.4700
-2.00%
CLRB Cellectar Biosciences, Inc.
3.0400
-5.30%
TIL Instil Bio, Inc.
10.41
-2.25%
ACHL Achilles Therapeutics plc
0.8000
-2.91%
EIGR Eiger BioPharmaceuticals, Inc.
1.7250
0.00%
ALGS Aligos Therapeutics, Inc.
0.7931
+0.78%
TBPH Theravance Biopharma, Inc.
9.20
-3.36%